Assembly Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Assembly Biosciences, Inc. (ASMB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $10.04 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2025-03-20
- Assembly Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $1.63, a 48.25% decline year-over-year.
- Assembly Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-03-31 was $3.15, a 67.66% decline year-over-year.
- Assembly Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-03-31 was $9.74, a 28.96% decline year-over-year.
- Assembly Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2019-03-31 was $13.71.
- Assembly Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $10.04, a 30.73% increase from fiscal 2023.
- Assembly Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $7.68, a 56.76% decline from fiscal 2022.
- Assembly Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $17.76, a 482.30% increase from fiscal 2021.
- Assembly Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $3.05, a 71.33% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $10.04 10-K · filed 2025-03-20 | ||||
| 2023-12-31 | $7.68 10-K · filed 2025-03-20 | ||||
| 2022-12-31 | $17.76 10-K · filed 2024-03-28 | $1.48 10-K · filed 2023-03-22 | |||
| 2022-09-30 | $1.48 10-Q · filed 2022-11-08 | ||||
| 2022-06-30 | $1.57 10-Q · filed 2022-08-09 | ||||
| 2022-03-31 | $1.63 10-Q · filed 2022-05-12 | ||||
| 2021-12-31 | $3.05 10-K · filed 2023-03-22 | ||||
| 2021-09-30 | $3.08 10-Q · filed 2022-11-08 | ||||
| 2021-06-30 | $3.12 10-Q · filed 2022-08-09 | ||||
| 2021-03-31 | $3.15 10-Q · filed 2022-05-12 | ||||
| 2020-12-31 | $10.64 10-K · filed 2022-03-11 | ||||
| 2020-09-30 | $11.01 10-Q · filed 2021-11-04 | ||||
| 2020-06-30 | $10.52 10-Q · filed 2021-08-05 | ||||
| 2020-03-31 | $9.74 10-Q · filed 2021-05-06 | ||||
| 2019-12-31 | $10.55 10-K · filed 2021-02-25 | ||||
| 2019-09-30 | $10.79 10-Q · filed 2020-11-05 | ||||
| 2019-06-30 | $12.68 10-Q · filed 2020-08-05 | ||||
| 2019-03-31 | $13.71 10-Q · filed 2020-05-08 | ||||
| 2018-12-31 | $30.84 10-K · filed 2021-02-25 | ||||
| 2017-12-31 | $17.37 10-K · filed 2020-03-04 | ||||
| 2012-06-30 | $5.06 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |